press releases • events & presentations
NeuroTrauma Sciences reported data on its novel neuroactive small molecule NTS-105 in a poster presentation at the 39th Annual Symposium of the National Neurotrauma Society in Atlanta, GA.
NeuroTrauma Sciences today provided an update on the development of its lead drug candidates NTS-104 and NTS-105 in traumatic brain injury.
Preclinical research to focus on sleep, inflammation and efficacy of the NTS compound NTS-104 in TBI
The study demonstrated the ability of NTS-105 to reduce cell death at a wide range of concentrations in preclinical models of TBI.
Dr. Parry will discuss recent advances in the development of novel neurosteroids for the treatment of traumatic brain injury.